| Identification | Back Directory | [Name]
AVN-944 | [CAS]
297730-17-7 | [Synonyms]
VX944
VX-944
VX 944
CS-1604
AVN944 (VX-944)
VX 944; AVN-944;
(R)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethylcarbamate
[(2R)-1-cyanobutan-2-yl] N-[(1S)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate
Carbamic acid, N-[(1S)-1-[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]ethyl]-, (1R)-1-(cyanomethyl)propyl ester | [Molecular Formula]
C25H27N5O5 | [MOL File]
297730-17-7.mol | [Molecular Weight]
477.51 |
| Chemical Properties | Back Directory | [Boiling point ]
597.4±50.0 °C(Predicted) | [density ]
1.277±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.52(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);62.83(Max Conc. mM) | [form ]
A crystalline solid | [pka]
11.38±0.46(Predicted) | [color ]
White to off-white | [InChIKey]
GYCPCOJTCINIFZ-OXJNMPFZSA-N | [SMILES]
N([C@@H](C)c1cc(ccc1)NC(=O)Nc2cc(c(cc2)c3[o]cnc3)OC)C(=O)O[C@H](CC)CC#N |
| Hazard Information | Back Directory | [Description]
AVN944 is a selective, noncompetitive inhibitor of inosine-5''-monophosphate dehydrogenase (IMPDH; Ki = 6-10 nM for both human IMPDH isoforms), a rate-limiting enzyme involved in the de novo synthesis of purine nucleotides. Inhibition of IMPDH results in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 has been shown to inhibit the proliferation of multiple myeloma cells in vitro by inducing caspase-independent apoptosis. It is also reported to have antitumor properties in androgen-sensitive and androgen-independent prostate cancer cells in vitro. | [Uses]
AVN-944 is a novel inosine monophosphate dehydrogenase (IMPDH) inhibitor. It has antiproliferative effects and might be combined with other agents for treatment of human prostate cancer.This compound is suitable for pyruvate dehydrogenase (PDH) related research. | [Enzyme inhibitor]
This orally available antineoplastic agent (FW = 310.36 g/mol; CAS 297730-17-7), also known as VX-944 and (R)-1-cyanobutan-2-yl-(S)-1-(3- (3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethyl)carbamate, inhibits inosine 5’-monophosphate dehydrogenase (IMPDH), the enzyme catalyzing the conversion of IMP into XMP, leading to the biosynthesis of GMP, GDP, GTP, and ultimately dGTP. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies, and AVN944 appears to have a selective cytotoxic effect on cancer cells. Reduction of GTP in normal cells results in a temporary slowing of cell growth only.AVN944 treatment results in dose-dependent cell growth inhibition in all studied prostate cancer cells, independently of their androgen sensitivity. AVN944 treatment arrests LNCaP cells in G1-phase and and androgen independent 22Rv1, DU145 and PC-3 cells in S-phase. AVN-944 treatment leads to the rapid disappearance of nucleostemin, a positive regulator of cell proliferation that is highly expressed in a variety of stem cells, tumors, and tumor cell lines. | [in vivo]
AVN-944 (0-150 mg/kg, Orally, twice daily) significantly increases the median survival time of leukemia model mice[2]. | Animal Model: | Balb/c mice (leukemia model, using Ba/F3 cells transduced with an activating human Flt-3 mutation injected into mice)[2] | | Dosage: | 75 or 150 mg/kg | | Administration: | Orally, twice daily | | Result: | Provided a significant increase in median survival time. Three of the 12 mice treated with 150 mg/kg AVN-944 were still alive on Day 35 when the study was terminated. |
| [IC 50]
Bax; Bak; Caspase 3; Caspase 8; Caspase 9 | [References]
[1] KENJI ISHITSUKA. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway[J]. Oncogene, 2005, 24 38: 5888-5896. DOI: 10.1038/sj.onc.1208739
[2] DANIEL FLORYK Timothy C T. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells[J]. International Journal of Cancer, 2008, 123 10: 2294-2302. DOI: 10.1002/ijc.23788 |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|